KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Other Operating Expenses (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Other Operating Expenses for 4 consecutive years, with $6.8 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Other Operating Expenses fell 55.8% year-over-year to $6.8 million, compared with a TTM value of $6.8 million through Sep 2024, down 80.34%, and an annual FY2024 reading of $91.1 million, up 252.98% over the prior year.
  • Other Operating Expenses was $6.8 million for Q4 2023 at AbCellera Biologics, up from $6.1 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $49.6 million in Q1 2022 and bottomed at $667000.0 in Q3 2020.
  • Average Other Operating Expenses over 4 years is $14.1 million, with a median of $7.6 million recorded in 2021.
  • The sharpest move saw Other Operating Expenses surged 2461.13% in 2021, then tumbled 87.04% in 2023.
  • Year by year, Other Operating Expenses stood at $32.7 million in 2020, then dropped by 15.36% to $27.7 million in 2021, then plummeted by 44.81% to $15.3 million in 2022, then plummeted by 55.8% to $6.8 million in 2023.
  • Business Quant data shows Other Operating Expenses for ABCL at $6.8 million in Q4 2023, $6.1 million in Q3 2023, and $6.5 million in Q2 2023.